STING activation was expected to convert cold tumors into inflamed, immune-responsive tumors.
The logic was straightforward: cGAS → STING → Type I interferon → dendritic cell activation → T-cell recruitment → tumor killing.
The pathway looked correct. The biology looked exciting. Confidence across oncology strategy teams was high.
Across multiple clinical programs, STING agonists repeatedly produced pharmacodynamic evidence of immune activation, but durable tumor responses remained limited.
In other words:
the pathway activates,
the biomarkers move,
but the therapy does not close.
No program has established the kind of durable efficacy that would support full topology closure.
Most summaries describe STING as a case of “insufficient efficacy.”
TAC reads it differently.
The deeper issue is not that STING fails to activate. The deeper issue is that activation itself has not translated into stable therapeutic closure.
This is why STING is not classified as a weak-mechanism target. It is classified as an intervention-direction closure problem.
This distinction is strategically important.
If the pathway were mechanistically wrong, the lesson would be simple: abandon the biology.
But STING shows something much harder: the biology may be right while the intervention still fails to become a durable therapy.
That makes STING a flagship contradiction case for TAC.
STING defines a recurring topology class:
strong upstream immune activation,
measurable pharmacodynamic response,
unresolved downstream clinical durability.
TAC labels this pattern as:
innate immune activation direction-closure contradiction archetype
STING is not presented here as an isolated example.
It defines a reusable topology precedent: a class of targets where upstream immune activation is reproducible, yet intervention-direction closure fails to emerge.
Similar structures are expected to appear across multiple tumor microenvironment activation programs.
In TAC, this case serves as the reference signature for identifying direction-closure instability in innate immune activation strategies.